ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -19 مورد

Comparison of conjugate vaccines against Haemophilus influenzae type b licensed in the United States

Comparison of conjugate vaccines against Haemophilus influenzae type b licensed in the United States
Vaccine
(commercial name)		 Carrier protein Recommended age of administration* Allergy considerations
Monovalent Hib vaccines
PRP-OMP (PedvaxHIB) Outer membrane protein complex of Neisseria meningitidis 2, 4, and 12 through 15 months Vial stoppers contain natural rubber latex
PRP-T (ActHIB) Tetanus toxoid 2, 4, 6, and 12 through 15 months Vial stoppers contain natural rubber latex
PRP-T (Hiberix) Tetanus toxoid 2, 4, 6, and 12 through 15 months Vial stoppers do not contain natural rubber latex
Combination Hib vaccine
DTaP-IPV/PRP-T (Pentacel) Tetanus toxoid 2, 4, 6, and 15 through 18 monthsΔ Vial stoppers do not contain natural rubber latex
DTaP, IPV, Hib, and HepB (Vaxelis) Outer membrane protein complex of N. meningitidis 2, 4, and 6 months of age◊ Vial stoppers do not contain natural rubber latex

DTaP: diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine; HepB: hepatitis B vaccine; Hib: H. influenzae type b; IPV: inactivated polio vaccine; PRP-OMP: polyribosylribitol phosphate conjugated to outer membrane protein complex of N. meningitidis; PRP-T: polyribosylribitol phosphate conjugated to tetanus toxoid.

* The first dose may be given as early as six weeks of age.

¶ Preferred for Native Americans and Alaskan natives.

Δ The booster (ie, fourth) dose may be given as early as 12 months of age, provided at least six months have elapsed since the third dose of DTaP.

◊ A monovalent Hib vaccine should be used for the booster dose at 12 to 15 months of age.
Prepared with data from:
  1. Briere EC, Rubin L, Moro PL, et al. Prevention and control of Haemophilus influenzae type b disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63:1.
  2. Hiberix [Haemophilus b conjugate vaccine (tetanus toxoid conjugate)]. US Food and Drug Administration (FDA) approved product information. Revised April 2018. US Food and Drug Administration. www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm (Accessed on May 2, 2018).
  3. Briere EC. Food and Drug Administration approval for use of Hiberix as a 3-dose primary Haemophilus influenzae type b (Hib) vaccination series. MMWR Morb Mortal Wkly Rep 2016; 65:418.
  4. Vaxelis (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, Haemophilus b conjugate [meningococcal protein conjugate] and hepatitis B [recombinant] vaccine). US Food and Drug Administration (FDA) approved product information. Revised December 2018. US Food and Drug Administration. www.fda.gov/BiologicsBloodVaccines/ucm629107.htm (Accessed on December 28, 2018).
Graphic 64312 Version 21.0